AlloDerm® versus Cortiva® in implant-based breast reconstruction: framework for a systematic review and meta-analysis of clinical and economic outcomes.

ABSTRACT:

Background

Acellular dermal matrices (ADMs) such as human-derived AlloDerm and Cortiva are widely used in implant-based breast reconstruction (IBBR) to provide soft-tissue support. AlloDerm is considered a standard ADM, while Cortiva (and its thinner variant, Cortiva Silhouette) is a newer alternative that may offer cost advantages. Individual studies including a recent randomized trial suggest Cortiva is non-inferior to AlloDerm in terms of clinical outcomes, with some evidence of lower seroma rates, and reduced material cost with Cortiva. To date, no comprehensive synthesis has focused specifically on comparing AlloDerm versus Cortiva in breast reconstruction. This protocol describes a systematic review and meta-analysis to evaluate differences in surgical complications, patient-

SUBMITTER: Tanas Y 

PROVIDER: S-EPMC12629042 | biostudies-literature | 2025 Nov

REPOSITORIES: biostudies-literature